ARCHIMED to acquire Esperion for $3.16 per share plus milestone payments

May 1, 2026 7:01 AM

Esperion Therapeutics (NASDAQ: ESPR) announced it has entered into a definitive agreement to be acquired by funds managed by ARCHIMED ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found